-
1 Comment
10x Genomics, Inc is currently in a long term uptrend where the price is trading 12.7% above its 200 day moving average.
From a valuation standpoint, the stock is 95.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 64.6.
10x Genomics, Inc's total revenue rose by 49.0% to $112M since the same quarter in the previous year.
Its net income has dropped by 5725.2% to $-416M since the same quarter in the previous year.
Finally, its free cash flow grew by 59911.6% to $71M since the same quarter in the previous year.
Based on the above factors, 10x Genomics, Inc gets an overall score of 4/5.
Industry | Health Information Services |
---|---|
Sector | Healthcare |
ISIN | US88025U1097 |
CurrencyCode | USD |
Exchange | NASDAQ |
Dividend Yield | 0.0% |
---|---|
Beta | 1.73 |
Target Price | 53.27 |
Market Cap | 6B |
PE Ratio | None |
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TXG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024